NCT06607302

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

RecruitingOBSERVATIONAL

Trial Details

Start: 2024-10-08Est. Completion: 2027-12

Enrollment target: 100 participants

Locations

Universitätsklinikum Augsburg, II. Medizinische Klinik, Augsburg, Germany
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda, Bad Liebenwerda, Germany
Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany
Onkologische Schwerpunktpraxis Bamberg, Bamberg, Germany
DRK Kliniken Berlin, Klinik für Innere Medizin, Berlin, Germany
Onkologisches Versorgungszentrum Berlin MVZ, Berlin, Germany
Sana Klinikum Lichtenberg, Innere Medizin IV, Berlin, Germany
Gemeinschaftspraxis Hämatologie - Onkologie, Dresden, Germany
Onkozentrum Dresden, Dresden, Germany
Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen, Germany
Universitätsklinikum Freiburg, Innere Medizin I, Freiburg im Breisgau, Germany
Onkologie Hannover, Hanover, Germany
Onkologie Hof, Hof, Germany
Medizinisches Versorgungszentrum Mönchengladbach, Mönchengladbach, Germany
TUM Klinikum Rechts der Isar, Klinik und Poliklinik für Innere Medizin II, München, Germany
Onkologisches Zentrum Passau, Passau, Germany

Intrahepatic Cholangiocarcinoma (Icc)

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…

Guangzhou, ChinaEst. completion Jan 2030

Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical CarcinomaMetastasis, Neoplasm

Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.